Sonova (OTCMKTS:SONVY) Shares Gap Down – What’s Next?

Sonova Holding (OTCMKTS:SONVY)’s share price gapped down before the market opened on Friday . The stock had previously closed at $51.69, but opened at $50.17. Sonova shares last traded at $52.3655, with a volume of 2,455 shares traded.

Analyst Upgrades and Downgrades

SONVY has been the topic of a number of recent analyst reports. Zacks Research lowered shares of Sonova from a “hold” rating to a “strong sell” rating in a research report on Tuesday, December 9th. BNP Paribas assumed coverage on shares of Sonova in a research note on Monday, October 20th. They issued an “underperform” rating for the company. Rothschild Redb upgraded Sonova from a “strong sell” rating to a “hold” rating in a research report on Monday, October 6th. Finally, Royal Bank Of Canada raised Sonova to a “moderate buy” rating in a report on Tuesday, November 18th. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, four have given a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold”.

Sonova Price Performance

The company has a current ratio of 1.24, a quick ratio of 0.91 and a debt-to-equity ratio of 0.51. The company has a fifty day simple moving average of $51.69 and a two-hundred day simple moving average of $55.49.

About Sonova

Sonova AG (OTCMKTS:SONVY) is a Switzerland-based provider of hearing care solutions, headquartered in Stäfa. The company designs, develops, manufactures and distributes a range of audiological products and related services aimed at improving hearing and communication for people with hearing loss. Its portfolio spans behind-the-ear and in-the-ear hearing instruments, wireless accessories and software solutions that enable connectivity with consumer devices and audiological fittings.

Sonova markets its products under several well-known brands, including Phonak and Unitron for hearing aids, and it is also associated with Advanced Bionics for cochlear implant systems.